Intellectus Partners LLC Buys 4,900 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellectus Partners LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 55,650 shares of the company’s stock after acquiring an additional 4,900 shares during the period. Intellectus Partners LLC’s holdings in Intellia Therapeutics were worth $1,697,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. bought a new stake in Intellia Therapeutics in the fourth quarter worth $26,000. Signaturefd LLC lifted its position in shares of Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after purchasing an additional 751 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Intellia Therapeutics by 95.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after purchasing an additional 1,108 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Intellia Therapeutics by 35.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after purchasing an additional 793 shares during the last quarter. Finally, Pathstone Family Office LLC lifted its position in shares of Intellia Therapeutics by 20.3% during the third quarter. Pathstone Family Office LLC now owns 6,438 shares of the company’s stock worth $204,000 after purchasing an additional 1,086 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares in the company, valued at $2,691,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on NTLA shares. The Goldman Sachs Group downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. Canaccord Genuity Group lifted their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Wedbush reiterated a “neutral” rating and set a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Finally, Wolfe Research started coverage on Intellia Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Intellia Therapeutics Price Performance

NTLA traded up $0.74 on Friday, hitting $20.76. The company had a trading volume of 1,025,682 shares, compared to its average volume of 1,154,036. The stock has a fifty day moving average price of $26.51 and a 200-day moving average price of $27.54. Intellia Therapeutics, Inc. has a 12-month low of $19.37 and a 12-month high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The company had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. During the same quarter in the previous year, the firm earned ($1.40) earnings per share. Research analysts anticipate that Intellia Therapeutics, Inc. will post -5.57 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.